M&A in Pharmaceuticals India's Pharmaceutical Industry on the Move: M&A Increases by 44.5%
With a booming biosimilars market, pharmerging India is set for further growth - Currently, the country's pahrmaceutical productiuon is valued at a staggerung US $ 15 billion per year...
New Delhi/India – The Indian domestic pharma market is estimated at INR 90,400 crore (US $ 15 billionn) ending 2015 with a growth of 12 %. It is estimated that almost 27-30 % of India's pharmaceutical market is catered to by multinationals operating in India and around 4,60,000 people are estimated to be employed in the pharmaceutical industry.
Top 20 companies account for 64 % of the market. 8 out of the top 20 are growing faster than the market, with Macleoids topping the list with 23.4% growth followed by Intas with 21. 3%, Cipla 19.7 % Glenmark over 19.4 % growth and Mankind 19.3 %.
Besides, India’s pharma exports stood at US $ 15.3 billion in 2014-15. There were M&A activities in the industry accounted for US $ 5.78, billion an increase of around 44.5 % in comparison to 2013.
The Government's continuous and concerted efforts have resulted in the reach of modern medicine to almost all corners of the country, and its measures have resulted in the steady decline of communicable diseases. The successful eradication of Polio, Small Pox etc. can be attributed entirely to the tireless efforts of the Government. The Ministry of Health and Family Welfare is responsible for the implementation of national health and family welfare programmes such as the prevention and control of major communicable diseases, maternal and child health.
Why India is the Coming Pharma Market
Public-private partnerships, an increased penetration of healthcare facilities in non-metro cities, involvement of multinationals in setting up facilities in the country, and establishment of educational institutions, are just a few multiple prime reasons enabling India to experience a surge in the global market.
Other key assets which have played a role in India becoming a leading pharma market are a thorough know-how in the manufacture of generics, rapidly developing research and development facilities with talented technical staffing, internationally recognised systems of pharmacy education, and a broad patient population pool enabling intense clinical trials.